Inozyme Pharma, Inc. (INZY) Stock Price, Financial Report, & Fundamental Analysis
NASDAQ:INZYInozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis.
(0.6)
Inozyme Pharma, Inc. Fundamental Analysis
Strength
| Analysis | # |
|---|---|
Price to Book (PBV) RatioUndervalued price-to-book. INZY stock price is under 1x the price-to-book value. |
|
Debt-Equity Ratio (DER)INZY equity is higher than it's debt. |
Weakness
| Analysis | # |
|---|---|
Market CapSmall market capitalization. Market capitalization is less than 2bn USD |
|
Revenue GrowthINZY has never had growing revenue. |
|
Net Income GrowthINZY has never had growing net income. |
|
Net IncomeINZY never has positive net income for 2 years. |
|
Dividend YieldINZY has low dividend yield (0%). |
|
Return of AssetsINZY has low return of asset (-43.68%). |
|
Return of EquityINZY has low return of equity (-55.2%). |
|
RevenueINZY never has positive revenue for 2 years. |
|
Return of Invested CapitalINZY has low ROIC. |
Competitors
Inozyme Pharma, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Income Statement
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- Revenue
- 0 USD
- Cost
- 0 USD
- Net Income
- -56,624,000 USD
- Profit Margin
- 0%
Cashflow Statement
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- 0 USD
Balance Sheet
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
| Quick Ratio | 1077.8% |
Long Term Liabilities
| Liquidity/Current Ratio | 1111.14% |
Dividend
| Dividend Yield | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend Payout Ratio (DPR) | 0% |
| Dividend per Share | 0,00 USD |
Financial Ratios
| Price to Earning (PER) | -0.4x |
| Price to Earning-Growth (PEG) | 0x |
| Price to Book Value (PBV) | 0x |
| Liquidity/Current Ratio | 1111.14% |
| Cash Ratio | 335.37% |
| Debt Ratio | 12.49% |
| Debt-Equity Ratio (DER) | 14.28% |
| Net Profit Margin (NPM) | 0% |
| Return of Assets (ROA) | -43.68% |
| Return of Equity (ROE) | -55.2% |
| Return on Capital Employed (ROCE) | -48.19% |
| Days of Sales Outstanding (DSO) | 0 |
| Days of Inventory Outstanding (DIO) | 0 |
| Days Payable Outstanding (DPO) | 0 |
| Operating Cycle (OC) | 0 |
| Cash Conversion Cycle (CCC) | 0 |
Inozyme Pharma, Inc. Executives
CEO
- CEO Name
- Mr. Axel Bolte
Management
Inozyme Pharma, Inc. Profile
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Additional Information
- Company name
- Inozyme Pharma, Inc.
- Symbol
- NASDAQ:INZY
- Exchange
- NASDAQ Global Select
- Industry
- Biotechnology
- Sector
- Healthcare
- Address
-
321 Summer Street
Boston
MA
US
02210 - Website
- https://www.inozyme.com